Neuropediatrics 2015; 46(02): 130-133
DOI: 10.1055/s-0034-1399753
Short Communications
Georg Thieme Verlag KG Stuttgart · New York

Pediatric Neurocysticercosis: Three Cases Presented in the Netherlands with Divergent Clinical Presentations

Laura A. van de Pol
1   Department of Child Neurology, VU University Medical Center, Amsterdam, The Netherlands
,
T. E. M. van Doeveren
1   Department of Child Neurology, VU University Medical Center, Amsterdam, The Netherlands
,
M. van der Kuip
2   Department of Pediatric Infectious Diseases and Immunology, VU University Medical Center, Amsterdam, The Netherlands
,
N. I. Wolf
1   Department of Child Neurology, VU University Medical Center, Amsterdam, The Netherlands
,
R. J. Vermeulen
1   Department of Child Neurology, VU University Medical Center, Amsterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

06 June 2014

15 November 2014

Publication Date:
02 February 2015 (online)

Abstract

Background Neurocysticercosis is a helminthic disease that affects the central nervous system by the larvae of the Taenia solium, the pork tapeworm. Because of the growing number of immigrants from endemic areas, its incidence is increasing in Western Europe.

Cases We describe three children, aged between 2 and 13 years, two of whom have a definite and one a probable diagnosis of neurocysticercosis based on the “Del Brutto criteria.” They presented with different symptoms and signs: symptomatic epilepsy, asymmetric cerebral palsy, and headache. Serological evaluation was negative in two of the three cases. All cases showed comparable abnormalities on magnetic resonance imaging of the brain: solitary or multiple, cystic lesions, with surrounding edema. In one of them, the “scolex” (part of the larvae) could be visualized. One case was treated with albendazole, the other two cases did not receive medication.

Conclusion A prompt diagnosis of neurocysticercosis by recognition of its typical brain lesions is important to prevent unnecessary diagnostic tests and treatment.

 
  • References

  • 1 Del Brutto OH. Neurocysticercosis. Continuum (Minneap Minn). Infect Dis 2012; 18: 1392-1416
  • 2 Garcia HH, Del Brutto OH ; Cysticercosis Working Group in Peru. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol 2005; 4 (10) 653-661
  • 3 Michelet L, Fleury A, Sciutto E , et al. Human neurocysticercosis: comparison of different diagnostic tests using cerebrospinal fluid. J Clin Microbiol 2011; 49 (1) 195-200
  • 4 Del Brutto OH, Rajshekhar V, White Jr AC , et al. Proposed diagnostic criteria for neurocysticercosis. Neurology 2001; 57 (2) 177-183
  • 5 Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997; 39 (4) 214-223
  • 6 Fabiani S, Bruschi F. Neurocysticercosis in Europe: Still a public health concern not only for imported cases. Acta Trop 2013; 128 (1) 18-26
  • 7 Rosenfeld EA, Byrd SE, Shulman ST. Neurocysticercosis among children in Chicago. Clin Infect Dis 1996; 23 (2) 262-268
  • 8 Singhi P, Singhi S. Neurocysticercosis in children. Indian J Pediatr 2009; 76 (5) 537-545
  • 9 Baird RA, Wiebe S, Zunt JR, Halperin JJ, Gronseth G, Roos KL. Evidence-based guideline: treatment of parenchymal neurocysticercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013; 80 (15) 1424-1429
  • 10 Lucato LT, Guedes MS, Sato JR, Bacheschi LA, Machado LR, Leite CC. The role of conventional MR imaging sequences in the evaluation of neurocysticercosis: impact on characterization of the scolex and lesion burden. AJNR Am J Neuroradiol 2007; 28 (8) 1501-1504
  • 11 Sáenz B, Ruíz-Garcia M, Jiménez E , et al. Neurocysticercosis: clinical, radiologic, and inflammatory differences between children and adults. Pediatr Infect Dis J 2006; 25 (9) 801-803
  • 12 Burneo JG, Escalaya AL, Gonzalez-Duarte A. Evidence-based guideline: Treatment of parenchymal neurocysticercosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2013; 81 (16) 1474-1476
  • 13 Garcia HH, Gonzales I, Lescano AG , et al; Cysticercosis Working Group in Peru. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis 2014; 14 (8) 687-695
  • 14 Singh G, White Jr AC. Determining better treatments for neurocysticercosis. Lancet Infect Dis 2014; 14 (8) 658-659